Figure 3.

Imaging characteristics of the patient during crizotinib treatment. Chest CT-enhanced scans were shown before (A) and 1 month (B), 2 months (C), and 6 months (D) after initiation of crizotinib therapy, demonstrating dramatic shrinkage of tumor lesions. E, Lumbar MRI after first-line therapy revealed an apparent enhancement of lesion at the L5 vertebral body after intensification, indicating the existence of bone metastases. F, Lumbar MRI after treatment with crizotinib for 2 months showed limited scope for reinforcement. MRI = magnetic resonance imaging.